Behandlung des kardiogenen Schocks im Rahmen eines akuten Myokardinfarkts

详细信息    查看全文

• 作者：S. Blazek ; K. Fengler ; T. Stiermaier ; P. Lurz ; G. Schuler ; Dr. G. Fürnau
• 关键词：Kardiogener Schock ; Akutes Koronarsyndrom ; Medikament?se Therapie ; Mechanische Unterstützungssysteme ; Cardiogenic shock ; Acute coronary syndrome ; Drug therapy ; Mechanical support
• 刊名：Herz
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：39
• 期：6
• 页码：702-710
• 全文大小：769 KB
• 参考文献：1. Goldberg RJ, Spencer FA, Gore JM et al (2009) Thirty-year trends (1975-005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 119:1211-219 g/10.1161/CIRCULATIONAHA.108.814947" target="_blank" title="It opens in new window">CrossRef
  2. Jeger RV, Radovanovic D, Hunziker PR et al (2008) Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 149:618-26 g/10.7326/0003-4819-149-9-200811040-00005" target="_blank" title="It opens in new window">CrossRef
  3. Babaev A, Frederick PD, Pasta DJ et al (2005) Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 294:448-54 g/10.1001/jama.294.4.448" target="_blank" title="It opens in new window">CrossRef
  4. Alexander JH, Reynolds HR, Stebbins AL et al (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297:1657-666 g/10.1001/jama.297.15.joc70035" target="_blank" title="It opens in new window">CrossRef
  5. Hasdai D, Harrington RA, Hochman JS et al (2000) Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 36:685-92 g/10.1016/S0735-1097(00)00814-7" target="_blank" title="It opens in new window">CrossRef
  6. Werdan K, Ru? M, Buerke M et al (2011) Deutsch-?sterreichische S3-Leitlinie Infarktbedingter kardiogener Schock. Diagnose, Monitoring und Therapie. Kardiologe 5:166-24 g/10.1007/s12181-011-0349-8" target="_blank" title="It opens in new window">CrossRef
  7. Cooper HA, Najafi AH, Ghafourian K et al (2014) Diagnosis of cardiogenic shock without the use of a pulmonary artery catheter. Eur Heart J Acute Cardiovasc Care [Epub ahead of print]
  8. Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569-619 g/10.1093/eurheartj/ehs289" target="_blank" title="It opens in new window">CrossRef
  9. Hochman JS, Sleeper LA, Webb JG et al (2006) Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 295:2511-515 g/10.1001/jama.295.21.2511" target="_blank" title="It opens in new window">CrossRef
  10. Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341:625-34 g/10.1056/NEJM199908263410901" target="_blank" title="It opens in new window">CrossRef
  11. Hochman JS, Sleeper LA, White HD et al (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285:190-92 g/10.1001/jama.285.2.190" target="_blank" title="It opens in new window">CrossRef
  12. Jeger RV, Urban P, Harkness SM et al (2011) Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: a pooled analysis of trials. Acute Card Care 13:14-0 g/10.3109/17482941.2010.538696" target="_blank" title="It opens in new window">CrossRef
  13. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999-054 g/10.1093/eurheartj/ehr236" target="_blank" title="It opens in new window">CrossRef
  14. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK et al (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569-619 g/10.1093/eurheartj/ehs215" target="_blank" title="It opens in new window">CrossRef
  15. Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367:1287-296 g/10.1056/NEJMoa1208410" target="_blank" title="It opens in new window">CrossRef
  16. Cavender MA, Milford-Beland S, Roe MT et al (2009) Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 104:507-13 g/10.1016/j.amjcard.2009.04.016" target="_blank" title="It opens in new window">CrossRef
  17. Webb JG, Lowe AM, Sanborn TA et al (2003) Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 42:1380-386 g/10.1016/S0735-1097(03)01050-7" target="_blank" title="It opens in new window">CrossRef
  18. White HD, Assmann SF, Sanborn TA et al (2005) Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 112:1992-001 g/10.1161/CIRCULATIONAHA.105.540948" target="_blank" title="It opens in new window">CrossRef
  19. Levine GN, Hochman JS (1995) Thrombolysis in acute myocardial infarction complicated by cardiogenic shock. J Thromb Thrombolysis 2:11-0 g/10.1007/BF01063156" target="_blank" title="It opens in new window">CrossRef
  20. Bonello L, De Labriolle A, Roy P et al (2008) Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock. Am J Cardiol 102:287-91 g/10.1016/j.amjcard.2008.03.052" target="_blank" title="It opens in new window">CrossRef
  21. Steg PG, van ?t Hof A, Hamm CW et al (2013) Bivalirudin started during emergency transport for primary PCI. N Engl J Med 369:2207-217 g/10.1056/NEJMoa1311096" target="_blank" title="It opens in new window">CrossRef
  22. Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218-230 g/10.1056/NEJMoa0708191" target="_blank" title="It opens in new window">CrossRef
  23. Asfar P, Meziani F, Hamel JF et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370:1583-593 g/10.1056/NEJMoa1312173" target="_blank" title="It opens in new window">CrossRef
  24. Fincke R, Hochman JS, Lowe AM et al (2004) Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 44:340-48 g/10.1016/j.jacc.2004.03.060" target="_blank" title="It opens in new window">CrossRef
  25. Thiele H, Zeymer U, Neumann FJ et al (2013) Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 382:1638-645 g/10.1016/S0140-6736(13)61783-3" target="_blank" title="It opens in new window">CrossRef
  26. Sakr Y, Reinhart K, Vincent JL et al (2006) Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 34:589-97 g/10.1097/01.CCM.0000201896.45809.E3" target="_blank" title="It opens in new window">CrossRef
  27. De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779-89 g/10.1056/NEJMoa0907118" target="_blank" title="It opens in new window">CrossRef
  28. De Luca L, Colucci WS, Nieminen MS et al (2006) Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27:1908-920 g/10.1093/eurheartj/ehi875" target="_blank" title="It opens in new window">CrossRef
  29. Delle Karth G, Buberl A, Geppert A et al (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47:1251-256 g/10.1046/j.1399-6576.2003.00252.x" target="_blank" title="It opens in new window">CrossRef
  30. Fuhrmann JT, Schmeisser A, Schulze MR et al (2008) Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 36:2257-266 g/10.1097/CCM.0b013e3181809846" target="_blank" title="It opens in new window">CrossRef
  31. Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997-003 g/10.1016/S0735-1097(02)02968-6" target="_blank" title="It opens in new window">CrossRef
  32. Koreny M, Geppert A, Wutte M et al (2000) Effects of milrinone on pulmonary gas exchange in catecholamine-dependent heart failure. Am J Cardiol 86:570-73, A510 g/10.1016/S0002-9149(00)01020-1" target="_blank" title="It opens in new window">CrossRef
  33. Cheng JM, Den Uil CA, Hoeks SE et al (2009) Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 30:2102-108 g/10.1093/eurheartj/ehp292" target="_blank" title="It opens in new window">CrossRef
  34. Kar B, Gregoric ID, Basra SS et al (2011) The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol 57:688-96 g/10.1016/j.jacc.2010.08.613" target="_blank" title="It opens in new window">CrossRef
  35. Sheu JJ, Tsai TH, Lee FY et al (2010) Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 38:1810-817 g/10.1097/CCM.0b013e3181e8acf7" target="_blank" title="It opens in new window">CrossRef
  36. Beurtheret S, Mordant P, Paoletti X et al (2013) Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J 34:112-20 g/10.1093/eurheartj/ehs081" target="_blank" title="It opens in new window">CrossRef
  37. Fuernau G, Thiele H (2011) Invasive circulation assist devices for intrahospital and interhospital transport. Notfall Rettungsmed 14:630-34 g/10.1007/s10049-011-1417-0" target="_blank" title="It opens in new window">CrossRef
  38. Burkhoff D, Cohen H, Brunckhorst C et al (2006) A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 152:469 e461–e468 g/10.1016/j.ahj.2006.05.031" target="_blank" title="It opens in new window">CrossRef
  39. Thiele H, Sick P, Boudriot E et al (2005) Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 26:1276-283 g/10.1093/eurheartj/ehi161" target="_blank" title="It opens in new window">CrossRef
  40. Kiernan MS, Krishnamurthy B, Kapur NK (2010) Percutaneous right ventricular assist via the internal jugular vein in cardiogenic shock complicating an acute inferior myocardial infarction. J Invasive Cardiol 22:E23–E26
  41. Prutkin JM, Strote JA, Stout KK (2008) Percutaneous right ventricular assist device as support for cardiogenic shock due to right ventricular infarction. J Invasive Cardiol 20:E215–E216
  42. Werdan K, Gielen S, Ebelt H et al (2014) Mechanical circulatory support in cardiogenic shock. Eur Heart J 35:156-67 g/10.1093/eurheartj/eht248" target="_blank" title="It opens in new window">CrossRef
  43. Kawashima D, Gojo S, Nishimura T et al (2011) Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO J 57:169-76 g/10.1097/MAT.0b013e31820e121c" target="_blank" title="It opens in new window">CrossRef
  44. Manzo-Silberman S, Fichet J, Mathonnet A et al (2013) Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. Resuscitation 84:609-15 g/10.1016/j.resuscitation.2012.10.001" target="_blank" title="It opens in new window">CrossRef
  45. Seyfarth M, Sibbing D, Bauer I et al (2008) A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52:1584-588 g/10.1016/j.jacc.2008.05.065" target="_blank" title="It opens in new window">CrossRef
  46. Cheung AW, White CW, Davis MK, Freed DH (2014) Short-term mechanical circulatory support for recovery from acute right ventricular failure: clinical outcomes. J Heart Lung Transplant [Epub ahead of print]
  47. Prondzinsky R, Lemm H, Swyter M et al (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 38:152-60 g/10.1097/CCM.0b013e3181b78671" target="_blank" title="It opens in new window">CrossRef
  48. Thiele H, Schuler G, Neumann FJ et al (2012) Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 163:938-45 g/10.1016/j.ahj.2012.03.012" target="_blank" title="It opens in new window">CrossRef
  49. Van Diepen S, Reynolds HR, Stebbins A et al (2014) Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Crit Care Med 42:281-88 g/10.1097/CCM.0b013e31829f6242" target="_blank" title="It opens in new window">CrossRef
  
• 作者单位：S. Blazek (1)
  K. Fengler (1)
  T. Stiermaier (1)
  P. Lurz (1)
  G. Schuler (1)
  Dr. G. Fürnau (1)
  
  1. Klinik für Innere Medizin/Kardiologie, Universit?t Leipzig -Herzzentrum, Strümpellstr. 39, 04289, Leipzig, Deutschland
  
• ISSN：1615-6692

文摘

While the mortality rate of acute myocardial infarction has decreased drastically in the last decades, the outcome of patients with cardiogenic shock complicating acute myocardial infarction is still devastating. The effectiveness of supportive medicinal therapy of cardiogenic shock is often limited by undesired side effects (e.g. arrhythmia and increased myocardial oxygen consumption) or inadequate hemodynamic support. Mechanical circulatory support in cardiogenic shock failed to show beneficial effects on short-term and long-term survival; however, there are hints for a survival benefit in therapy refractory cardiogenic shock. Therefore, future trials need to evaluate further medicinal treatment options and also the best type of mechanical support as well as the optimal time of initiation to improve the success of therapeutic management.